Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Thomas Müller. (2018) Safinamide: an add-on treatment for managing Parkinson’s disease. Clinical Pharmacology: Advances and Applications 10, pages 31-41.
Read now
Read now
Thomas Müller. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Review of Neurotherapeutics 17:12, pages 1135-1144.
Read now
Read now
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Thomas Müller. (2017) Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 13:6, pages 693-699.
Read now
Read now
Sharon L. Chan & Eng-King Tan. (2017) Targeting LRRK2 in Parkinson’s disease: an update on recent developments. Expert Opinion on Therapeutic Targets 21:6, pages 601-610.
Read now
Read now
Thomas Müller. (2016) Emerging approaches in Parkinson’s disease – adjunctive role of safinamide. Therapeutics and Clinical Risk Management 12, pages 1151-1160.
Read now
Read now
Qu Qi, Lijuan Cao, Feiyan Li, Hong Wang, Huiying Liu, Haiping Hao & Kun Hao. (2015) Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats. Xenobiotica 45:9, pages 820-827.
Read now
Read now
Thomas Müller. (2015) Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opinion on Investigational Drugs 24:6, pages 737-742.
Read now
Read now
Supriyo Choudhury, Richeek Pradhan, Pritikanta Paul, Manisha Das, Anupam Gupta, Pahari Ghosh & Suparna Chatterjee. (2014) Profile of levodopa-induced dyskinesia in patients of Parkinson’s disease: a record based study. Neurological Research 36:9, pages 841-846.
Read now
Read now
Stephen A. Buetow, Alison Talmage, Clare McCann, Laura Fogg & Suzanne Purdy. (2014) Conceptualizing how group singing may enhance quality of life with Parkinson’s disease. Disability and Rehabilitation 36:5, pages 430-433.
Read now
Read now
Thomas Müller. (2013) Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Review of Neurotherapeutics 13:9, pages 969-977.
Read now
Read now
Thomas Müller. (2013) Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations. Expert Opinion on Drug Metabolism & Toxicology 9:8, pages 1015-1024.
Read now
Read now
Thomas Müller. (2010) New small molecules for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 19:9, pages 1077-1086.
Read now
Read now
Thomas Müller. (2010) Entacapone. Expert Opinion on Drug Metabolism & Toxicology 6:8, pages 983-993.
Read now
Read now
Thomas Müller. (2009) Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference. Patient Preference and Adherence 3, pages 51-59.
Read now
Read now
Thomas Müller. (2008) Role of homocysteine in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics 8:6, pages 957-967.
Read now
Read now
Articles from other publishers (48)
M. T. Pellecchia, M. Picillo, M. C. Russillo, V. Andreozzi, C. Oliveros & C. Cattaneo. (2023) The effects of safinamide according to gender in Chinese parkinsonian patients. Scientific Reports 13:1.
Crossref
Crossref
Jocelyn J. Chang, Sanjay R.V. Gadi, Aleksandar Videnovic, Braden Kuo & Trisha S. Pasricha. (2023) Impact of outpatient gastroenterology consult on pharmacotherapy and management of gastrointestinal symptoms in Parkinson’s Disease. Clinical Parkinsonism & Related Disorders 9, pages 100215.
Crossref
Crossref
Zohre Sadeghian, Shahla Eyvari-Brooshghalan, Mohammadmahdi Sabahi, Nahal Nourouzi & Rasool Haddadi. (2022) Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease. Neuroscience Letters 790, pages 136884.
Crossref
Crossref
Ashish Patel, Stuti Patel, Meshwa Mehta, Yug Patel, Dhruv Langaliya, Shyam Bhalodiya & Tushar Bambharoliya. (2022) Recent Update on the Development of Leucine-Rich Repeat Kinase 2
(LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson’s
Disease. Medicinal Chemistry 18:7, pages 757-771.
Crossref
Crossref
Valeria Conti, Viviana Izzo, Maria Claudia Russillo, Marina Picillo, Marianna Amboni, Cesa L. M. Scaglione, Alessandra Nicoletti, Ilaria Cani, Calogero E. Cicero, Emanuela De Bellis, Bruno Charlier, Valentina Giudice, Gerardina Somma, Graziamaria Corbi, Paolo Barone, Amelia Filippelli & Maria Teresa Pellecchia. (2022) Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease. Frontiers in Medicine 9.
Crossref
Crossref
J. B. de Luccas, B. L. Bianqueti, A. Fim Neto, M. S. Rocha, A. K. Takahata, D. C. Soriano & F. Godinho. 2022. XXVII Brazilian Congress on Biomedical Engineering. XXVII Brazilian Congress on Biomedical Engineering
2211
2217
.
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2853
2870
.
Oleg S. Levin, Olga V. Iakovleva, Irina I. Coloman & Anastasia V. Kuzmina. (2021) Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?. Clinical and Translational Neuroscience 5:2, pages 18.
Crossref
Crossref
Laura Andreoli, Morteza Abbaszadeh, Xiao Cao & Maria Angela Cenci. (2021) Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. Neurobiology of Disease 157, pages 105429.
Crossref
Crossref
De-Qi Jiang, Qing-Min Zang, Li-Lin Jiang, Yan Wang, Ming-Xing Li & Jing-Yi Qiao. (2021) Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson’s disease: a systematic review and meta-analysis. Naunyn-Schmiedeberg's Archives of Pharmacology 394:9, pages 1893-1905.
Crossref
Crossref
Anmol Gulati, Charles S. Yeung, Blair Lapointe, Solomon D. Kattar, Hakan Gunaydin, Jack D. Scott, Kaleen K. Childers, Joey L. Methot, Vladimir Simov, Ravi Kurukulasuriya, Barbara Pio, Greg J. Morriello, Ping Liu, Haiqun Tang, Santhosh Neelamkavil, Harold B. Wood, Vanessa L. Rada, Michael J. Ardolino, Xin Cindy Yan, Rachel Palte, Karin Otte, Robert Faltus, Janice Woodhouse, Laxminarayan G. Hegde, Paul Ciaccio, Ellen C. Minnihan, Erin F. DiMauro, Matthew J. Fell, Peter H. Fuller & J. Michael Ellis. (2021) Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. RSC Medicinal Chemistry 12:7, pages 1164-1173.
Crossref
Crossref
Etienne Goubault, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Davide Martino, Justyna Sarna, Oury Monchi & Christian Duval. (2020) Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease. Tremor and Other Hyperkinetic Movements 10:1.
Crossref
Crossref
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Etienne Goubault, Hung P. Nguyen, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Justyna Sarna, Oury Monchi & Christian Duval. (2019) Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Frontiers in Neurology 10.
Crossref
Crossref
Paula Perez-Pardo, Laus M. Broersen, Tessa Kliest, Nick van Wijk, Amos Attali, Johan Garssen & Aletta D. Kraneveld. (2018) Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease. Frontiers in Aging Neuroscience 10.
Crossref
Crossref
Jong-Suep Baek, Jie Kai Tee, Yi Yun Pang, Ern Yu Tan, Kah Leong Lim, Han Kiat Ho & Say Chye Joachim Loo. (2018) Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson’s Disease. NeuroMolecular Medicine 20:2, pages 262-270.
Crossref
Crossref
Thomas Müller & Paul Foley. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clinical Pharmacokinetics 56:3, pages 251-261.
Crossref
Crossref
Elena V. Filatova, Maria I. Shadrina, Timur A. Kolomin, Ludmila A. Andreeva, Nikolay F. Myasoedov & Petr A. Slominsky. (2016) Synthetic Peptides Affect the Expression of <i>Gdnf</i> and Gdnf Receptors in Rats with 6-OHDA-Induced PD-Like Parkinsonism. World Journal of Neuroscience 06:04, pages 243-259.
Crossref
Crossref
Jun Tsugawa, Rieko Onozawa, Jiro Fukae, Takayasu Mishima, Shinsuke Fujioka & Yoshio Tsuboi. (2015) Impact of insufficient drug efficacy of antiparkinson agents on patient’s quality of life: a cross-sectional study. BMC Neurology 15:1.
Crossref
Crossref
Thomas Müller. (2015) Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease. Drugs 75:2, pages 157-174.
Crossref
Crossref
Ah-Reum Doo, Seung-Nam Kim, Dae-Hyun Hahm, Hye Hyun Yoo, Ji-Yeun Park, Hyejung Lee, Songhee Jeon, Jongpil Kim, Seong-Uk Park & Hi-Joon Park. (2014) Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model. BMC Complementary and Alternative Medicine 14:1.
Crossref
Crossref
Eva Schaeffer, Andrea Pilotto & Daniela Berg. (2014) Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease. CNS Drugs 28:12, pages 1155-1184.
Crossref
Crossref
Marlene C. Hechtner, Thomas Vogt, York Zöllner, Sabrina Schröder, Julia B. Sauer, Harald Binder, Susanne Singer & Rafael Mikolajczyk. (2014) Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism & Related Disorders 20:9, pages 969-974.
Crossref
Crossref
Julia J. Didonet, Judney C. Cavalcante, Lisiane de S. Souza, Miriam S.M.O. Costa, Eunice André, Vanessa de P. Soares-Rachetti, Remo Guerrini, Girolamo Calo’ & Elaine C. Gavioli. (2014) Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. Behavioural Brain Research 266, pages 29-36.
Crossref
Crossref
Anthony A. Estrada, Bryan K. Chan, Charles Baker-Glenn, Alan Beresford, Daniel J. Burdick, Mark Chambers, Huifen Chen, Sara L. Dominguez, Jennafer Dotson, Jason Drummond, Michael Flagella, Reina Fuji, Andrew Gill, Jason Halladay, Seth F. Harris, Timothy P. Heffron, Tracy Kleinheinz, Donna W. Lee, Claire E. Le Pichon, Xingrong Liu, Joseph P. Lyssikatos, Andrew D. Medhurst, John G. Moffat, Kevin Nash, Kimberly Scearce-Levie, Zejuan Sheng, Daniel G. Shore, Susan Wong, Shuo Zhang, Xiaolin Zhang, Haitao Zhu & Zachary K. Sweeney. (2014) Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors. Journal of Medicinal Chemistry 57:3, pages 921-936.
Crossref
Crossref
Erwin E. H. van Wegen, Mark A. Hirsch, Marijn Huiskamp & Gert Kwakkel. (2014) Harnessing Cueing Training for Neuroplasticity in Parkinson Disease. Topics in Geriatric Rehabilitation 30:1, pages 46-57.
Crossref
Crossref
Jean-François Daneault, Benoit Carignan, Abbas F Sadikot, Michel Panisset & Christian Duval. (2013) Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?. BMC Medicine 11:1.
Crossref
Crossref
Thomas Müller. (2013) Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease. Clinical Neuropharmacology 36:3, pages 84-91.
Crossref
Crossref
O.M. Littrell, J.L. Fuqua, A.D. Richardson, J. Turchan-Cholewo, E.R. Hascup, P. Huettl, F. Pomerleau, L.H. Bradley, D.M. Gash & G.A. Gerhardt. (2013) A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides 47:1, pages 43-49.
Crossref
Crossref
Manfred Gerlach, Paul Halley, Peter Riederer & Maarten van den Buuse. (2012) The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson’s disease: differential role of α2 adrenergic mechanisms. Journal of Neural Transmission 120:1, pages 31-36.
Crossref
Crossref
Thomas Müller. (2012) Drug therapy in patients with Parkinson’s disease. Translational Neurodegeneration 1:1.
Crossref
Crossref
Manfred Gerlach, Peter Riederer & Dieter Scheller. (2011) Mechanisms underlying and medical management of l-Dopa-associated motor complications. Journal of Neural Transmission 118:12, pages 1659-1660.
Crossref
Crossref
Manfred Gerlach, Gerd D. Bartoszyk, Peter Riederer, Olivia Dean & Maarten van den Buuse. (2011) Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Journal of Neural Transmission 118:12, pages 1733-1742.
Crossref
Crossref
Manfred Gerlach, Jürgen Beck, Peter Riederer & Maarten van den Buuse. (2011) Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Journal of Neural Transmission 118:12, pages 1727-1732.
Crossref
Crossref
Hashem Haghdoost-Yazdi, Ayda Faraji, Negin Fraidouni, Mohadeseh Movahedi, Elham Hadibeygi & Fatemeh Vaezi. (2011) Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease. Behavioural Brain Research 223:1, pages 70-74.
Crossref
Crossref
Pedro J. Garcia-Ruiz. (2011) Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Historical review. Journal of the Neurological Sciences 307:1-2, pages 15-17.
Crossref
Crossref
EL Lane & GA Smith. (2010) Understanding graft-induced dyskinesia. Regenerative Medicine 5:5, pages 787-797.
Crossref
Crossref
Amal Alachkar, Jonathan M. Brotchie & Owen T. Jones. (2010) Locomotor response to l-DOPA in reserpine-treated rats following central inhibition of aromatic l-amino acid decarboxylase: Further evidence for non-dopaminergic actions of l-DOPA and its metabolites. Neuroscience Research 68:1, pages 44-50.
Crossref
Crossref
Amal Alachkar, Jonathan M. Brotchie & Owen T. Jones. (2010) Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human α2-adrenergic and dopaminergic receptors. Neuroscience Research 67:3, pages 245-249.
Crossref
Crossref
Thomas Müller. (2010) The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1169.
Crossref
Crossref
Chong-Han Pek, Raymond C.S. Seet, Jing-Hui Yik & Erle C.H. Lim. (2010) Orofacial dystonia triggered by mouth closure. Clinical Neurology and Neurosurgery 112:1, pages 79-81.
Crossref
Crossref
S. Patel, K. Lorincz, R. Hughes, N. Huggins, J. Growdon, D. Standaert, M. Akay, J. Dy, M. Welsh & P. Bonato. (2009) Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors. IEEE Transactions on Information Technology in Biomedicine 13:6, pages 864-873.
Crossref
Crossref
F. Valldeoriola, S. Cobaleda & J. Lahuerta. (2009) A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: The ROPI-PARK Study. Clinical Neurology and Neurosurgery 111:9, pages 742-747.
Crossref
Crossref
Alan Haycox, Christophe Armand, Susana Murteira, John Cochran & Clément François. (2009) Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting. Drugs & Aging 26:9, pages 791-801.
Crossref
Crossref
Sébastien MontelAnne-Marie Bonnet & Catherine Bungener. (2009) Quality of Life in Relation to Mood, Coping Strategies, and Dyskinesia in Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology 22:2, pages 95-102.
Crossref
Crossref
Kerstin Buck & Boris Ferger. (2008) Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: A bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiology of Disease 29:2, pages 210-220.
Crossref
Crossref
Pia Jensen, Matthias Bauer, Charlotte H. Jensen, Hans R. Widmer, Jan B. Gramsbergen, Morten Blaabjerg, Jens Zimmer & Morten Meyer. (2007) Expansion and characterization of ventral mesencephalic precursor cells: Effect of mitogens and investigation of FA1 as a potential dopaminergic marker. Journal of Neuroscience Research 85:9, pages 1884-1893.
Crossref
Crossref
James W. Tetrud. (2014) Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease. CNS Spectrums 12:4, pages 275-286.
Crossref
Crossref